Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery

被引:2
|
作者
Xiong, Anning [1 ]
Li, Changhui [1 ]
Xu, Jianlin [1 ]
Yang, Xiaohua [1 ]
Nie, Wei [1 ]
Zhong, Hua [1 ]
Chu, Tianqing [1 ]
Zhang, Wei [1 ]
Zhong, Runbo [1 ]
Pan, Feng [1 ]
Shen, Yinchen [1 ]
Lou, Yuqing [1 ]
Zhang, Bo [1 ]
Han, Baohui [1 ]
Zhang, Xueyan [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, 241 Huaihai West Rd, Shanghai 200030, Peoples R China
关键词
Histologic subtype; Distant metastasis; Non-Small cell lung cancer; RESPIRATORY SOCIETY CLASSIFICATION; INTERNATIONAL-ASSOCIATION; CANCER; IMPACT; SURVIVAL; FEATURES; DISEASE; PROGNOSIS; RISK;
D O I
10.1016/j.lungcan.2021.02.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed to explore the prognostic significance of solid pattern for bone metastases (BM) in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients after surgery. A total of 237 stage I-III lung adenocarcinoma patients with EGFR mutation were analyzed after procedure. The patients were divided into four groups: the solid-present patients with BM, the solid-absent patients with BM, the solid-present patients without BM and the solid-absent patients without BM. The bone disease-free survival (bDFS), systemic disease-free survival (DFS) and overall survival (OS) were assessed. The results revealed that the patients with solid pattern had shorter DFS (15 months vs. 19 months; P < 0.001) and OS (47 months vs. 77 months; P = 0.001). Moreover, bDFS of solid-present patients was significantly shorter than solid-absent patients (27 months vs. 14 months; P < 0.001). In addition, patients with solid component had worsened bDFS, no matter with BM as first-site development (12.5 months vs. 16.5 months; P = 0.016) or nonfirst-site development (16.5 months vs. 45.5 months; P < 0.001). These findings suggested that solid pattern predicted worse DFS and OS and also showed shortened interval between surgery and BM.
引用
收藏
页码:124 / 130
页数:7
相关论文
共 50 条
  • [1] Solid Subtype Predicts Early Bone Metastases in Sensitive EGFR-Mutated Lung Adenocarcinoma Patients After Surgery
    Xiong, A.
    Li, C.
    Xu, J.
    Yang, X.
    Nie, W.
    Zhong, H.
    Chu, T.
    Zhang, W.
    Zhong, R.
    Pan, F.
    Shen, Y.
    Lou, Y.
    Zhang, B.
    Han, B.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S966 - S967
  • [2] PATIENTS WITH EGFR-MUTATED LUNG ADENOCARCINOMA AFTER PROGRESSION
    Li, Ling
    Tian, Jiyuan
    Sun, Haiyan
    ACTA MEDICA MEDITERRANEA, 2023, 39 (03): : 707 - 713
  • [3] A nomogram for predicting brain metastases of EGFR-mutated lung adenocarcinoma patients and estimating the efficacy of therapeutic strategies
    Wang, Jing
    Zhang, Baozhong
    Pang, Qingsong
    Zhang, Tian
    Chen, Xi
    Er, Puchun
    Wang, Yuwen
    You, Jinqiang
    Wang, Ping
    JOURNAL OF THORACIC DISEASE, 2021, 13 (02) : 883 - 892
  • [4] Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
    Kim, In Ae
    Lee, Jong Sik
    Kim, Hee Joung
    Kim, Wan Seop
    Lee, Kye Young
    BMC CANCER, 2018, 18
  • [5] High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases
    Lagana, Marta
    Gurizzan, Cristina
    Roca, Elisa
    Cortinovis, Diego
    Signorelli, Diego
    Pagani, Filippo
    Bettini, Anna
    Bonomi, Lucia
    Rinaldi, Silvia
    Berardi, Rossana
    Filetti, Marco
    Giusti, Raffaele
    Pilotto, Sara
    Milella, Michele
    Intagliata, Salvatore
    Baggi, Alice
    Cortellini, Alessio
    Soto Parra, Hector
    Brighenti, Matteo
    Petrelli, Fausto
    Bennati, Chiara
    Bidoli, Paolo
    Garassino, Marina Chiara
    Berruti, Alfredo
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [6] Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without EGFR-mutated Lung Adenocarcinoma
    Li, Ming-Hsien
    Tsai, Jo-Ting
    Ting, Lai-Lei
    Lin, Jang-Chun
    Liu, Yu-Chang
    IN VIVO, 2018, 32 (01): : 203 - 209
  • [7] Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma
    Luo, Jizhuang
    Wang, Rui
    Han, Baohui
    Zhang, Jie
    Zhao, Heng
    Fang, Wentao
    Luo, Qingquan
    Yang, Jun
    Yang, Yunhai
    Zhu, Lei
    Chen, Tianxiang
    Cheng, Xinghua
    Huang, Qingyuan
    Wang, Yiyang
    Zheng, Jiajie
    Chen, Haiquan
    ONCOTARGET, 2017, 8 (04) : 7050 - 7058
  • [8] Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma
    Ma, Xiaoyan
    Zhu, Hui
    Guo, Hongbo
    Han, Anqin
    Wang, Haiyong
    Jing, Wang
    Zhang, Yan
    Kong, Li
    Yu, Jinming
    ONCOTARGET, 2016, 7 (49) : 81906 - 81917
  • [9] Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma
    Yamanaka, Yumie
    Seki, Yoshitaka
    Ishikawa, Takeo
    Kuwano, Kazuyoshi
    BMJ CASE REPORTS, 2019, 12 (01)
  • [10] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Yoshida, Tatsuya
    Ishii, Genichiro
    Goto, Koichi
    Yoh, Kiyotaka
    Niho, Seiji
    Umemura, Shigeki
    Matsumoto, Shingo
    Ohmatsu, Hironobu
    Nagai, Kanji
    Ohe, Yuichiro
    Ochiai, Atsushi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (10) : 1691 - 1700